Phase 3 Safety and Efficacy Study of I.V. Iclaprim v Linezolid in cSSSI (ASSIST-1)

NCT00299520 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

INDUSTRY

Sponsor class

Conditions

Complicated Skin and Skin Structure Infection

Interventions

DRUG: intravenous iclaprim or intravenous linezolid

Sponsor

Arpida AG